

## Literatur für onkologie heute 03/2021

### SCHWERPUNKT: ZNS- UND KOPF-HALS-TUMOREN

#### Einsatz der Aminosäure-PET in der Hirntumordiagnostik (S. 9–16)

*N. Galldiks, K.-J. Langen*

1. Brandsma D et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. *Lancet Oncol* 2008; 9: 453–61
2. Okada H et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. *Lancet Oncol* 2015; 16 :e534–42
3. Galldiks N et al. Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. *Neuro Oncol* 2020; 22: 17–30
4. Langen KJ et al. Advances in neuro-oncology imaging. *Nat Rev Neurol* 2017; 13: 279–89
5. Galldiks N et al. From the clinician's point of view – What is the status quo of positron emission tomography in patients with brain tumors? *Neuro Oncol* 2015; 17: 1434–44
6. Kratochwil C et al. Intra-individual comparison of (18)F-FET and (18)F-DOPA in PET imaging of recurrent brain tumors. *Neuro Oncol* 2014; 16: 434–40
7. Langen KJ et al. Imaging of amino acid transport in brain tumours: Positron emission tomography with O-(2-[(18)F]fluoroethyl)-L-tyrosine (FET). *Methods* 2017; 130: 124–34
8. Albert NL et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. *Neuro Oncol* 2016; 18: 1199–208
9. Law I et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0. *Eur J Nucl Med Mol Imaging* 2019; 46: 540–57
10. Galldiks N et al. PET imaging in patients with brain metastasis-report of the RANO/PET group. *Neuro Oncol* 2019; 21: 585–95
11. Rapp M et al. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. *J Nucl Med* 2013; 54: 229–35
12. Pichler R et al. Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance? *Eur J Nucl Med Mol Imaging* 2010; 37: 1521–8
13. Dunet V et al. Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and metaanalysis. *J Nucl Med* 2012; 53: 207–14
14. Unterrainer M et al. (18)F-FET PET Uptake Characteristics in Patients with Newly Diagnosed and Untreated Brain Metastasis. *J Nucl Med* 2017; 58: 584–9
15. Zhao C et al. A meta-analysis on the diagnostic performance of (18)F-FDG and (11)C-methionine PET for differentiating brain tumors. *AJNR Am J Neuroradiol* 2014; 35: 1058–65
16. Hutterer M et al. [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. *Neuro Oncol* 2013; 15: 341–51
17. Sala Q et al. 18F-DOPA, a clinically available PET tracer to study brain inflammation? *Clin Nucl Med* 2014; 39: e283–518.
18. Hutterer M et al. Epileptic Activity Increases Cerebral Amino Acid Transport Assessed by 18F-Fluoroethyl-L-Tyrosine Amino Acid PET: A Potential Brain Tumor Mimic. *J Nucl Med* 2017; 58: 129–37

19. Burghaus L et al. FET PET in Primary Central Nervous System Vasculitis. *Clin Nucl Med* 2018; 43: e322–e3
20. Jansen NL et al. MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? *Eur J Nucl Med Mol Imaging* 2012; 39: 1021–9
21. Galldiks N et al. Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET – Clinical relevance in glioma patients. *Neuro Oncol* 2019; 21(10): 1331–38
22. Suchorska B et al. Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma. *Neuro Oncol* 2018; 20: 279–88
23. Kunz M et al. Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas. *Neuro Oncol* 2019; 21(2): 274–84
24. Pauleit D et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. *Brain* 2005; 128: 678–87
25. Kunz M et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. *Neuro Oncol* 2011; 13: 307–16
26. Verburg N et al. Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study. *Neuro Oncol* 2020; 22: 412–22
27. Schön S et al. Imaging glioma biology: spatial comparison of amino acid PET, amide proton transfer, and perfusion-weighted MRI in newly diagnosed gliomas. *Eur J Nucl Med Mol Imaging* 2020; 47: 1468–75
28. Song S et al. Simultaneous FET-PET and contrast-enhanced MRI based on hybrid PET/MR improves delineation of tumor spatial biodistribution in gliomas: a biopsy validation study. *Eur J Nucl Med Mol Imaging* 2020; 47: 1458–67
29. Galldiks N et al. Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. *Eur J Nucl Med Mol Imaging* 2010; 37: 84–92
30. Lohmann P et al. FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma. *Eur J Nucl Med Mol Imaging* 2019; 46: 591–602
31. Pöpperl G. Value of O-(2-[18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. *Eur J Nucl Med Mol Imaging* 2004; 31: 1464–70
32. Galldiks N et al. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. *Eur J Nucl Med Mol Imaging* 2015; 42: 685–95
33. Rachinger W et al. Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. *Neurosurgery* 2005; 57: 505–11
34. Mihovilovic MI et al. O-(2-((18)F)fluoroethyl)-L-tyrosine PET for the differentiation of tumour recurrence from late pseudoprogression in glioblastoma. *J Neurol Neurosurg Psychiatry* 2019; 90: 238–9
35. Mehrkens JH et al. The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment. *J Neurooncol* 2008; 88: 27–35
36. Jena A et al. Glioma Recurrence Versus Radiation Necrosis: Single-Session Multiparametric Approach Using Simultaneous O-(2-18F-Fluoroethyl)-L-Tyrosine PET/MRI. *Clin Nucl Med* 2016; 41: e228–36
37. Pyka T et al. Diagnosis of glioma recurrence using multiparametric dynamic 18F-fluoroethyl-tyrosine PET-MRI. *Eur J Radiol* 2018; 103: 32–738.
38. Galldiks N et al. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. *Neuro Oncol* 2015; 17: 1293–300

39. Herrmann K et al. Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients. *Neuro Oncol* 2014; 16: 603–9
40. Minamimoto R et al. Differentiation of Brain Tumor Recurrence from Post-Radiotherapy Necrosis with 11C-Methionine PET: Visual Assessment versus Quantitative Assessment. *PLoS one* 2015; 10: e013251541
41. Nihashi T et al. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. *AJNR Am J Neuroradiol* 2013; 34: 944–50
42. Salber D et al. Differential uptake of O-(2-18F-fluoroethyl)-L-tyrosine, L-3H-methionine, and 3H-deoxyglucose in brain abscesses. *J Nucl Med* 2007; 48: 2056–62
43. Terakawa Y et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. *J Nucl Med* 2008; 49: 694–9
44. Tsuyuguchi N et al. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? *J Neurosurg* 2003; 98: 1056–64
45. Lizarraga KJ et al. (18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment. *J Nucl Med* 2014; 55: 30–6
46. Cicone F et al. Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery. *Eur J Nucl Med Mol Imaging* 2015; 42: 103–11
47. Galldiks N et al. Role of O-(2-18F-Fluoroethyl)-L-Tyrosine PET for Differentiation of Local Recurrent Brain Metastasis from Radiation Necrosis. *J Nucl Med* 2012; 53: 1367–74
48. Ceccon G et al. Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy. *Neuro Oncol* 2017; 19: 281–8
49. Romagna A et al. Suspected recurrence of brain metastases after focused high dose radiotherapy: can [18F]FET-PET overcome diagnostic uncertainties? *Radiat Oncol* 2016; 11: 139
50. Kebir S et al. Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases. *Neuro Oncol* 2016; 18: 1462–4
51. Galldiks N et al. Treatment Monitoring of Immunotherapy and Targeted Therapy using (18)F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences. *J Nucl Med* 2020; jnumed.120.248278
52. Wen PY et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. *J Clin Oncol* 2010; 28: 1963–7253
53. Macdonald DR et al. Response criteria for phase II studies of supratentorial malignant glioma. *J Clin Oncol* 1990; 8: 1277–80
54. Ahluwalia MS, Wen PY. Antiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directions. *Expert Rev Anticancer Ther* 2011; 11: 653–6
55. Dhermain FG et al. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. *Lancet Neurol* 2010; 9: 906–20
56. Kumar AJ et al. Malignant gliomas: MR imaging spectrum of radiation therapy - and chemotherapy -induced necrosis of the brain after treatment. *Radiology* 2000; 217: 377–84
57. Galldiks N et al. Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. *Eur J Nucl Med Mol Imaging* 2006; 33: 516–24
58. Galldiks N et al. Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. *Mol Imaging* 2010; 9: 40–6

59. Herholz K et al. Monitoring the effect of chemotherapy in a mixed glioma by C-11-methionine PET. *J Neuroimaging* 2003; 13: 269–71
60. Galldiks N et al. Amino Acid PET - An Imaging Option to Identify Treatment Response, Posttherapeutic Effects, and Tumor Recurrence? *Front Neurol* 2016; 7: 120
61. Ceccon G et al. Early treatment response assessment using (18)F-FET PET compared to contrast-enhanced MRI in glioma patients following adjuvant temozolomide chemotherapy. *J Nucl Med* 2020; jnumed.120.254243
62. Wyss M et al. Early metabolic responses in temozolomide treated low-grade glioma patients. *J Neurooncol* 2009; 95: 87–93
63. Roelcke U et al. Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas. *Neuro Oncol* 2016; 18: 744–51
64. Suchorska B et al. (18)F-FET-PET as a biomarker for therapy response in non-contrast enhancing glioma following chemotherapy. *J Neurooncol* 2018; 139: 721–30
65. Piroth MD et al. Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. *Int J Radiat Oncol Biol Phys* 2011; 80: 176–84
66. Galldiks N et al. Assessment of treatment response in patients with glioblastoma using [18F]Fluoroethyl-L-Tyrosine PET in comparison to MRI. *J Nucl Med* 2012; 53: 1048–57
67. Reithmeier T et al. Bevacizumab as salvage therapy for progressive brain stem gliomas. *Clin Neurol Neurosurg* 2013; 115: 165–9
68. Galldiks N et al. Earlier diagnosis of progressive disease during bevacizumab treatment using O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography in comparison with magnetic resonance imaging. *Mol Imaging* 2013; 12: 273–6
69. Galldiks N et al. Discrepant MR and [(18)F]Fluoroethyl-L-Tyrosine PET Imaging Findings in a Patient with Bevacizumab Failure. *Case Rep Oncol* 2012; 5: 490–4
70. Morana G et al. Multimodal magnetic resonance imaging and 18F-L-dihydroxyphenylalanine positron emission tomography in early characterization of pseudoresponse and nonenhancing tumor progression in a pediatric patient with malignant transformation of ganglioglioma treated with bevacizumab. *J Clin Oncol* 2013; 31: e1–5
71. Hutterer M et al. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. *J Nucl Med* 2011; 52: 856–64
72. Galldiks N et al. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]fluoroethyl-L-tyrosine PET in comparison to MRI. *Eur J Nucl Med Mol Imaging* 2013; 40: 22–33
73. Schwarzenberg J et al. Treatment Response Evaluation Using 18F-FDOPA PET in Patients with Recurrent Malignant Glioma on Bevacizumab Therapy. *Clin Cancer Res* 2014; 20: 3550–9
74. Galldiks N et al. Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine. *Eur J Nucl Med Mol Imaging* 2018; 45: 2377–86

## **Checkpoint-Antikörper bei fortgeschrittenen Kopf-Hals-Tumoren: Deutliche Verbesserung des Outcomes bei sehr guter Verträglichkeit (S. 25–28)**

*J. Roters, M. R. Müller*

1. Hodi FS et al. Improved survival with ipilimumab in patients with metastatic melanoma. *New Engl J Med* 2010; 363: 711–23
2. Garon EB et al. Pembrolizumab for the treatment of non-small-cell lung cancer. *New Engl J Med* 2015; 372: 2018–28
3. Paz-Ares L et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. *New Engl J Med* 2018; 379: 2040–51
4. Horn L et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. *New Engl J Med* 2018; 379: 2220–29
5. Rini BI et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *New Engl J Med* 2019; 380: 1116–27
6. André T et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. *New Engl J Med* 2020; 383: 2207–18
7. Ansell SM et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. *New Engl J Med* 2015; 372: 311–19
8. Kaufman HL et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. *Lancet Oncol* 2016; 17: 1374–85
9. Finn RS et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. *New Engl J Med* 2020; 382: 1894–905.
10. Rosenberg JE et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. *Lancet* 2016; 387: 1909–20
11. Cohen EEW et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. *Lancet* 2019; 393: 156–67
12. Burtneß B et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. *Lancet* 2019; 394: 1915–28
13. Ferris RL et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. *New Engl J Med* 2016; 375: 1856–67
14. Ferris RL et al. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. *Clin Cancer Res* 2019; 25: 5221–30
15. Harrington KJ et al. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. *Lancet Oncol* 2017; 18: 1104–15
16. Zandberg DP et al. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with  $\geq 25\%$  tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. *Eur J Cancer* 2019; 107: 142–52
17. Ferris RL et al. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. *Ann Oncol* 2020; 31: 942–50